Loading clinical trials...
Loading clinical trials...
Treatment Modification and Symptom Burden in High-Risk Dialysis Patients
Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects. Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.
Age
All ages
Sex
ALL
Healthy Volunteers
No
The Rogosin Institute
New York, New York, United States
Start Date
January 1, 2013
Primary Completion Date
September 1, 2014
Completion Date
September 1, 2014
Last Updated
October 9, 2018
16
ACTUAL participants
Treatment modification
OTHER
Lead Sponsor
The Rogosin Institute
Collaborators
NCT07146854
NCT04163614
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04580420